1 week ago
Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib).
The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer.
Lung Cancer Trial Shows Benefit
The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer.
This trial is the first randomized Phase 3 study evaluating a selective RET kinase inhibitor as adjuvant therapy, reinforcing the value of genomic testing in cancer treatment.
In addition, the overall safety profile of selpercatinib was consistent with previous studies, and detailed results are expected to be presented at an upcoming medical congress. The trial enrolled 151 patients who received either selpercatinib or placebo, marking a significant step in the treatment of early-stage lung cancer.
The broader market experienced a mixed day on the previous trading day, with the S&P 500 futures down ...
